subcultured on tryticase soy agar with 5% sheep blood and chocolate agar; small, smooth, non-hemolytic, catalase and oxidase-positive colonies were observed. The isolated bacteria were biochemically identified by Vitek-2 system (bioMérieux, Marcy-l'Étoile, France) as Moraxella group, which include Moraxella osloensis (M. osloensis), M. lacunata and M. nonliquefaciens. Species identification was achieved by gene amplification and sequencing. The resulting sequence of the partial 16S rRNA gene yielded 99% identity to the strain CIP 68.36 of M. nonliquefaciens (accession number: JN75343).
In order to test β-lactamase production, chromogenic cephalosporin nitrocefin disk test was used as reference method (1). Antimicrobial susceptibility was determined by the Kirby-Bauer disk diffusion method as recommended by the Clinical and Laboratory Standards Institute (M45-A2). The bacterial isolate showed susceptibility to amoxicillin/clavulanic acid, cotrimoxazole and azithromycin.
The genus Moraxella consists of aerobic, gramnegative coccobacilli, which are a part of the normal flora in human skin and mucosal surfaces. The main natural habitat of M. nonliquefaciens is most probably the human nasal cavity, and this organism has mostly been isolated from respiratory and ocular sites (2). Even though M. nonliquefaciens can be considered a saprophytic organism in humans, some cases of infection caused by this organism have been reported: infective endocarditis (3), septic arthritis (4), thyroiditis (5), endophthalmitis (6,7), pulmonar infection (8) and sepsis (9). Dear Dr. Wallace, Thank you for your thoughts and comments on our paper "Travel distance and home dialysis rates in the United States". With regards to the designation of home dialysis units, our data came from the end-stage renal disease (ESRD) networks directly and not from the USRDS database. As such, we were able to request more specific detail for this study. Each facility designated as a home dialysis facility had at least 1 patient there on a home dialysis modality (either peritoneal dialysis (PD) or home hemodialysis (HHD)) and this was confirmed with ESRD network 10, where the data was compiled.
CorresPonDenCe
With regards to the distances presented in the paper, we ran 2 separate analyses for the paper (not mentioned in the abstract because of space limits) -1 with all patients in the study (177, 606) and 1 with only the patients who dialyzed at units with both in-center hemodialysis (IHD) and a home dialysis modalities (PD, HHD or both). The adjusted analyses contained many factors that were felt to potentially influence modality utilization in addition to travel distance. It was felt by our reviewers that the patients attending facilities without home dialysis options may not truly have a choice of modality, hence we limited the sample to patients attending facilities with both IHD and home modalities. When all 177,606 patients were included in the distance calculations, the median travel distances to patients' initial dialysis facilities were 5.7 miles, 12.6 miles, and 17.8 miles, respectively for IHD, PD, and HHD patients, respectively (Table 1) . Comparatively, these respective distances for the group attending facilities with home dialysis and IHD options were 5.4 miles, 3.5 miles, and 6.5 miles, respectively (Table 1) .
Although the median distances are similar, the mean distances indicate that the limited sample patients may live further from IHD facilities, but closer to home dialysis facilities and also traveled farther to their initial facilities. For the overall sample (177,606 patients), the
